Prestige Biopharma scouts sales expert from AbbVie

Prestige Biopharma said Tuesday that it has hired Dr. Julien Rea from AbbVie as the director of Global Commercial Operations to lead the global commercialization of its Herceptin biosimilar Tuznue (trastuzumab).

Director Rea, who holds a master's degree in marketing from EM Lyon Business School and a Ph.D. in Pharmacy from the University of Lyon, has extensive experience in global pharmaceutical companies, including Servier, Abbott, and AbbVie, where he led the sales strategy for the Humira portfolio, exceeding revenue targets for five consecutive years. He is recognized for his financial excellence in profit-loss management, business valuation, and supply management.

In anticipation of Tuznue’s European advance, Prestige Biopharma has made several organizational changes, including recruiting Director Rea and appointing a supply chain expert from Beringer Ingelheim.

Based on more than 20 years of global marketing and sales experience, Rea will lead the commercialization strategy for the company's biosimilar pipeline and antibody drugs, including Tuznue.

Rea recently made his first official appearance at ESMO ASIA 2024 in Singapore. During the congress, Prestige Biopharma's booth received visits from healthcare professionals worldwide, and Director Rea actively promoted the company's flagship anticancer products.

“We are focusing on our commercialization strategy based on the European approval of Tuznue,” a Prestige Biopharma official said. “We will accelerate developing new markets for new biosimilars based on Director Rea's expertise.”